Medtronic ($MDT) submitted unspecified concessions to the European Commission in a bid to close its $43 billion bid for Covidien ($COV) by early 2015. Overcoming antitrust concerns in various regions is one of the last impediments to the transaction. Last month, Covidien sold its clinical-stage drug-coated balloon to please antitrust authorities in the U.S. The European Commission will decide whether to approve the transaction by Nov. 28. News